Formulation and evaluation of mucoadhesive dosage form containing rosiglitazone maleate.
Extending the residence time of a dosage form at a particular site and controlling the release of drug from the dosage form are useful especially for achieving controlled plasma level of the drug as well as improving bioavailability. The objective of this study was to extend the GI residence time of the dosage form and control the release of rosiglitazone using mucoadhesive tablet to achieve controlled plasma level of the drug which is especially useful after 8 to 12 weeks of monotherapy using conventional dosage forms when dose is doubled and plasma level also doubles. Direct compression method using simplex lattice design, followed by optimization of the evaluation parameters was employed to get final optimized formulation. The optimized formulation showed a mucoadhesive strength >40 gm-f, and a mucoadhesion time >12 hours with release profile closer to the target release profile and followed Non-Fickian diffusion mediated release of rosiglitazone maleate.
Krishna
Shiva S
SS
Department of Pharmaceutics, Krupanidhi College of Pharmacy, 5 Sarjapur Road, Koramangala, Bangalore-560034, India.
Ray
Subhabrata
S
Thakur
R S
RS
D000269:Adhesives; D002626:Chemistry, Pharmaceutical; D004304:Dosage Forms; D004339:Drug Compounding; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D007700:Kinetics; D010316:Particle Size; D000077154:Rosiglitazone; D012995:Solubility; D013607:Tablets; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D000269:Adhesives; D004304:Dosage Forms; D007004:Hypoglycemic Agents; D013607:Tablets; D045162:Thiazolidinediones; D000077154:Rosiglitazone